Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector newsTweets 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2012 | 07:59am CET

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
02:03a DAIICHI SANKYO : and ArQule Announce the Completion of the METIV-HCC Phase 3 Stu..
02/16 DAIICHI SANKYO : Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive ..
02/15 DAIICHI SANKYO : to close R&D sites in India and Japan
02/15 DAIICHI SANKYO : Strengthens Authorized Generic Business through Daiichi Sankyo ..
02/13 DAIICHI SANKYO : Announces Further Reorganization of its Research & Development ..
02/06 DAIICHI SANKYO : Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive ..
02/02 DAIICHI SANKYO : Studies from Daiichi Sankyo Have Provided New Information about..
02/02 DAIICHI SANKYO : Announces Continuation of Mobile Healthcare Field Clinic Servic..
01/31 DAIICHI SANKYO : Announces New Chairman and President
01/26 STUDIES CONDUCTED AT DAIICHI SANKYO : physicochemical properties and structural..
More news
Sector news : Pharmaceuticals - NEC
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/17 ArQule's lead product candidate tivantinib flunks late-stage liver cancer stu..
02/03 FDA rejects Charleston and Daiichi's opioid candidate
01/24 Pancreatic Cancer Field Awaits Sparse Data
01/18 Daiichi launches Japan-based study of breast cancer candidate U3-1402
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Financials ( JPY)
Sales 2017 940 485 M
EBIT 2017 -
Net income 2017 72 254 M
Finance 2017 299 419 M
Yield 2017 2,72%
P/E ratio 2017 23,69
P/E ratio 2018 25,92
EV / Sales 2017 1,62x
EV / Sales 2018 1,69x
Capitalization 1 822 159 M
More Financials
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 12
Average target price 2 400  JPY
Spread / Average Target -6,6%
Consensus details
EPS Revisions
More Estimates Revisions
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results